美罗华-话题@MedSci

#美罗华#

9篇内容 | 1004人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317166, encodeId=2199131e1661c, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=美罗华再迎新对手，第二款国产利妥昔单抗上市, objectType=article, longId=201962, objectId=c3af201962c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3af201962c0, replyNumber=0, likeNumber=52, createdTime=2020-10-12, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3af201962c0, moduleTitle=美罗华再迎新对手，第二款国产利妥昔单抗上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3af201962c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317165, encodeId=3ca1131e1651a, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, objectType=article, longId=191492, objectId=9a9c19149256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9c19149256, replyNumber=0, likeNumber=34, createdTime=2020-04-06, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9c19149256, moduleTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9c19149256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317164, encodeId=2009131e16402, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价, objectType=article, longId=187232, objectId=b01918e23299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01918e23299, replyNumber=0, likeNumber=36, createdTime=2020-02-04, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01918e23299, moduleTitle=辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01918e23299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317163, encodeId=07a3131e1630f, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=FDA开始优先审查来那度胺与美罗华联合治疗淋巴瘤的潜力, objectType=article, longId=161426, objectId=ed5a161426e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed5a161426e0, replyNumber=0, likeNumber=33, createdTime=2019-03-02, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed5a161426e0, moduleTitle=FDA开始优先审查来那度胺与美罗华联合治疗淋巴瘤的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed5a161426e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317162, encodeId=2a72131e16232, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功, objectType=article, longId=122645, objectId=70ef12264515, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ef12264515, replyNumber=0, likeNumber=36, createdTime=2017-12-09, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ef12264515, moduleTitle=Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ef12264515)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317161, encodeId=41e0131e161d2, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, objectType=article, longId=90445, objectId=632a904456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632a904456c, replyNumber=0, likeNumber=38, createdTime=2017-03-04, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632a904456c, moduleTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632a904456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317160, encodeId=47a2131e1605f, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=NEJM：美罗华相对硫唑嘌呤更有利于ANCA-相关血管炎的治疗, objectType=article, longId=43446, objectId=6107434467e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107434467e, replyNumber=0, likeNumber=43, createdTime=2014-12-01, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107434467e, moduleTitle=NEJM：美罗华相对硫唑嘌呤更有利于ANCA-相关血管炎的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6107434467e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317159, encodeId=1098131e159c0, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=姜文奇：利妥昔单抗美罗华临床应用15年的回顾与展望, objectType=article, longId=38314, objectId=a83938314d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a83938314d6, replyNumber=0, likeNumber=33, createdTime=2014-07-30, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a83938314d6, moduleTitle=姜文奇：利妥昔单抗美罗华临床应用15年的回顾与展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a83938314d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317158, encodeId=8ee2131e15873, content=<a href='/topic/show?id=9181e99846e' target=_blank style='color:#2F92EE;'>#美罗华#</a>, objectTitle=罗氏旗下白血病新药Obinutuzumab可能优于美罗华, objectType=article, longId=19018, objectId=282819018b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282819018b7, replyNumber=0, likeNumber=40, createdTime=2013-05-22, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282819018b7, moduleTitle=罗氏旗下白血病新药Obinutuzumab可能优于美罗华, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282819018b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

美罗华

2020-05-29

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

美罗华再迎新对手，第二款国产利妥昔单抗上市

2020-10-12

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准

2020-04-06

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价

2020-02-04

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

FDA开始优先审查来那度胺与美罗华联合治疗淋巴瘤的潜力

2019-03-02

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功

2017-12-09

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

[药企软文]重磅！美罗华生物仿制药在欧洲获得批准

2017-03-04

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

NEJM：美罗华相对硫唑嘌呤更有利于ANCA-相关血管炎的治疗

2014-12-01

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

姜文奇：利妥昔单抗美罗华临床应用15年的回顾与展望

2014-07-30

yhj-time (审核中...)

前往app查看评论内容

#美罗华#

罗氏旗下白血病新药Obinutuzumab可能优于美罗华

2013-05-22

科室
- - 订阅+
  - 更多科室
工具
服务